Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Oncotype DX testing pays off even for the smallest, lowest-risk breast cancers. A large study of over 100,000 patients found that genomic risk stratification meaningfully guided treatment decisions in ultra–low-risk HR-positive breast cancer — and patients who tested high-risk and received chemotherapy had significantly better survival outcomes. The 5-year overall survival was 97.2% in tested patients vs. 93.6% in untested ones.
Genomic testing isn't just for obvious high-risk cases — it matters even in the smallest, most favorable breast cancers. A new study published in The Oncologist, using data from over 350,000 patients in the U.S. National Cancer Database, found that Oncotype DX testing had clinically meaningful impact on survival outcomes in patients with ultra–low-risk, node-negative, hormone receptor–positive (HR+) breast cancer (T1mi/a/b, pN0–pN1mi).
Among the 11,196 patients with a high recurrence score (RS ≥26) — a group traditionally considered low-risk by tumor size alone — those who received adjuvant chemotherapy had significantly better overall survival than those who didn't. The benefit held up even after propensity score matching, reinforcing that the genomic signal, not just clinical features, is driving the difference.
By the Numbers:
Why it matters: These findings reinforce that tumor biology — not just size or node status — should drive treatment decisions. Genomic testing in seemingly "safe" cancers can uncover patients who genuinely benefit from chemotherapy, supporting a more personalized approach to breast cancer care.
